Latest Breaking News On - மொட்டி பார்பிசிதஎன் - Page 1 : comparemela.com

Press release content from Business Wire. The AP news staff was not involved in its creation. Can-Fite Expands its Phase II COVID-19 Study to Europe April 22, 2021 GMT PETACH TIKVA, Israel (BUSINESS WIRE) Apr 22, 2021 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the expansion of its Phase II COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized, double blind, placebo-controlled study is evaluating the benefits of treatment of Piclidenoson plus standard supportive care (SSC) vs. placebo plus SSC in patients hospitalized with moderate to severe COVID-19, as defined by the U.S. National Institutes of Health Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Patients are randomized in a 1:1 ratio to receive 2 mg Piclidenoson twice daily or placebo, and treated for up to 28

United statesFite biopharmaMotti farbsteinPnina fishmanExchange commissionFite biopharma ltdDrug administrationHealth coronavirus diseaseOrphan drug designationFast track designationCan fite biopharma ltdBusiness wireஒன்றுபட்டது மாநிலங்களில்மொட்டி பார்பிசிதஎன்ப்ணிந மீன்பரிமாற்றம் தரகு